Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV EPS (Basic)

EPS (Basic) at other companies

Alkermes logo
AlkermesALKS
-$0.40-386%
JAN
Janus Living JAN
-$2.14-1,327%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's EPS (basic)?
Indivior Pharmaceuticals, Inc. (INDV) reported EPS (basic) of $0.71 in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's EPS (basic) changed year-over-year?
Indivior Pharmaceuticals, Inc. 's EPS (basic) increased by 86.8% year-over-year, from $0.38 to $0.71.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's EPS (basic)?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's EPS (basic) has grown at a 77.6% compound annual growth rate (CAGR), from -$0.30 to $1.68.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.